Advancing Vaccine Technology to Combat Global Pandemic Threats - New technologies such as virus-like particles are promising weapons in the battle against pandemic influenza. - BioPharm International

ADVERTISEMENT

Advancing Vaccine Technology to Combat Global Pandemic Threats
New technologies such as virus-like particles are promising weapons in the battle against pandemic influenza.


BioPharm International Supplements


Conclusions

The prospect of using platform production strategies, both upstream and downstream for the rapid production of pandemic vaccines is becoming a reality. The major bottlenecks and time constraints imposed by current egg-based or mammalian cell culture manufacturing strategies could be alleviated by switching to a platform microbial production process. There are a number of such systems currently in development that in real terms will significantly reduce the vaccine's time-to-market and ultimately save lives.

ANDREW CLUTTERBUCK is the downstream purification team leader, NITIN JAIN is a downstream purification scientist, and DAVID SIMPSON is the process development manager, all at Eden Biodesign, Ltd, Liverpool, UK, +44 151 728 1750,

References

1. Jeffery K. Taubenberger JK, Morens DM. 1918 Influenza: the Mother of All Pandemics. Emerg Infect Dis. 2006 Jan;12(1)15–22 Available from: http://www.cdc.gov/eid.

2. Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/h1n1flu/images.htm.

3. Roche provides additional donation of 5.65 million packs of Tamiflu to World Health Organization. Roche Media News. 12 May 2009. Available from: http://www.roche.com/med-cor-2009-05-12-e.pdf.

4. Technical data reproduced with kind permission from iQur, Ltd. (London, UK) Available from: http://www.iqur.com/.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here